119TH CONGRESS	C	
1st Session	5.	

To establish statutory rights to choose to receive, provide, and cover fertility treatments, and for other purposes.

IN THE SENATE OF THE UNITED STATES

Ms. Duckworth (for herself, Mrs. Murray, Mr. Booker, Mr. Schumer, Mr. Reed, Ms. Warren, Mr. Padilla, Mr. Welch, Ms. Cantwell, Mr. Fetterman, Mr. Hickenlooper, Mr. Merkley, Mr. Schatz, Mr. Warner, Ms. Klobuchar, Ms. Alsobrooks, Mr. Coons, Mr. King, Mr. Blumenthal, Mr. Whitehouse, Mr. Sanders, Mr. Peters, Mr. Gallego, Mr. Durbin, Mr. Heinrich, Ms. Hirono, Mrs. Shaheen, and Ms. Rosen) introduced the following bill; which was read twice and referred to the Committee on ______

A BILL

To establish statutory rights to choose to receive, provide, and cover fertility treatments, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Protect IVF Act".
- 5 SEC. 2. PURPOSES.
- 6 The purposes of this Act are as follows:

TAM25686 3S5 S.L.C.

(1) To permit patients to seek and receive fertility treatment, including assisted reproductive technology services, and to permit health care providers that choose to provide fertility treatment, to provide such services without States enacting harmful or unwarranted limitations or requirements that single out the provision of assisted reproductive services for restrictions that are not consistent with widely accepted and evidence-based medical standards of care, and which do not significantly advance reproductive health or the efficacy and safety of fertility treatment, or make fertility treatment more difficult to access.

- (2) To promote the right and ability of a patient residing in any State to choose to receive fertility treatment provided in accordance with widely accepted and evidence-based medical standards of care by a health care provider who chooses to provide such services.
- (3) To protect an individual's right to make decisions, in consultation with the individual's health care provider, about the most appropriate medical care to maximize the chance of becoming pregnant and giving birth to a healthy, living, human child with the help of fertility treatment.

1	SEC.	3.	DEFINITIONS
1	SEC.	3.	DEFINITIONS

2	In this Act:
3	(1) Fertility treatment.—The term "fer-
4	tility treatment" includes the following:
5	(A) Preservation of human oocytes, sperm,
6	or embryos.
7	(B) Artificial insemination, including
8	intravaginal insemination, intracervical insemi-
9	nation, and intrauterine insemination.
10	(C) Assisted reproductive technology, in-
11	cluding in vitro fertilization and other treat-
12	ments or procedures in which reproductive ge-
13	netic material, such as oocytes, sperm, and em-
14	bryos, are handled, when clinically appropriate.
15	(D) Genetic testing of embryos.
16	(E) Medications prescribed or obtained
17	over-the-counter, as indicated for fertility.
18	(F) Gamete donation.
19	(G) Such other information, referrals,
20	treatments, procedures, medications, laboratory
21	testing, technologies, and services relating to
22	fertility as the Secretary of Health and Human
23	Services determines appropriate.
24	(2) HEALTH CARE PROVIDER.—The term
25	"health care provider" means any entity or indi-
26	vidual (including any physician, nurse practitioner,

1	physician assistant, pharmacist, health care support
2	personnel, clinical staff, and any other individual, as
3	determined by the Secretary of Health and Human
4	Services) that—
5	(A) is engaged or seeks to engage in the
6	delivery of fertility treatment, including through
7	the provision of evidence-based information
8	counseling, referrals, or items and services that
9	relate to, aid in, or provide fertility treatment
10	and
11	(B) if required by State law to be licensed
12	certified, or otherwise authorized to engage in
13	the delivery of such services—
14	(i) is so licensed, certified, or other-
15	wise authorized; or
16	(ii) would be so licensed, certified, or
17	otherwise authorized but for the fact that
18	the individual or entity has provided, is
19	providing, or plans to provide fertility
20	treatment in accordance with section 4.
21	(3) HEALTH INSURANCE ISSUER.—The term
22	"health insurance issuer" has the meaning given
23	such term in section 2791(b) of the Public Health
24	Service Act (42 U.S.C. 300gg-91(b)).

1	(4) Manufacturer.—The term "manufac
2	turer" means the manufacturer of a drug or device
3	approved, cleared, authorized, or licensed under sec
4	tion 505, $510(k)$, $513(f)(2)$, or 515 of the Federa
5	Food, Drug, and Cosmetic Act (21 U.S.C. 355
6	360(k), $360e(f)(2)$, $360e)$ or section 351 of the Pub
7	lic Health Service Act (42 U.S.C. 262) or otherwise
8	legally marketed.
9	(5) State.—The term "State" includes each or
10	the 50 States, the District of Columbia, Puerto Rico
11	each territory and possession of the United States
12	and any political subdivision thereof.
13	(6) Widely accepted and evidence-basei
14	MEDICAL STANDARDS OF CARE.—The term "widely
15	accepted and evidence-based medical standards of
16	care" means any medical services, procedures, and
17	practices that are in accordance with the guidelines
18	of the American Society for Reproductive Medicine
19	SEC. 4. FERTILITY TREATMENT RIGHTS.
20	(a) General Rule.—
21	(1) Individual Rights.—An individual has a
22	statutory right under this Act, without prohibition
23	limitation, interference, or impediment, to the extensi
24	that such prohibition, limitation, interference, or im
25	pediment in any way or degree obstructs, delays, or

1	affects commerce over which the Federal Govern-
2	ment has jurisdiction, to—
3	(A) receive fertility treatment from a
4	health care provider, in accordance with widely
5	accepted and evidence-based medical standards
6	of care;
7	(B) continue or complete an ongoing fer-
8	tility treatment previously initiated by a health
9	care provider, in accordance with widely accept-
10	ed and evidence-based medical standards of
11	care;
12	(C) make decisions and arrangements re-
13	garding the donation, testing, use, storage, or
14	disposition of their own reproductive genetic
15	material; and
16	(D) establish contractual agreements with
17	a health care provider relating to the health
18	care provider's services in handling, testing,
19	storing, shipping, and disposing of the individ-
20	ual's reproductive genetic material in accord-
21	ance with widely accepted and evidence-based
22	medical standards of care.
23	(2) Health care provider rights.—A
24	health care provider has a statutory right under this
25	Act, without prohibition, limitation, interference, or

1	impediment, to the extent that such prohibition, lim-
2	itation, interference, or impediment in any way or
3	degree obstructs, delays, or affects commerce over
4	which the Federal Government has jurisdiction, to—
5	(A) choose to provide, or assist with the
6	provision of, fertility treatment provided in ac-
7	cordance with widely accepted and evidence-
8	based medical standards of care;
9	(B) continue or complete the provision of,
10	or assistance with, fertility treatment that was
11	lawful when commenced and is provided in ac-
12	cordance with widely accepted and evidence-
13	based medical standards of care;
14	(C) provide for, or assist with, the testing,
15	use, storage, or disposition of reproductive ge-
16	netic material in accordance with widely accept-
17	ed and evidence-based medical standards of
18	care; and
19	(D) establish contractual agreements with
20	individuals or manufacturers relating to the
21	health care provider's services in handling, test-
22	ing, storing, shipping, and disposing of the indi-
23	vidual's reproductive genetic material.
24	(3) Health insurance issuer rights.—A
25	health insurance issuer has a statutory right under

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

TAM25686 3S5 S.L.C.

this Act, without prohibition, limitation, interference, or impediment, to the extent that such prohibition, limitation, interference, or impediment in any way or degree obstructs, delays, or affects commerce over which the Federal Government has jurisdiction, to choose to cover the provision of fertility treatment provided in accordance with widely accepted and evidence-based medical standards of care.

(4) Manufacturer rights.—A manufacturer of a drug or device that is approved, cleared, authorized, licensed under section 505,510(k), 513(f)(2), or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355; 360(k); 360c(f)(2); 360e) or section 351 of the Public Health Service Act (42 U.S.C. 262) or otherwise legally marketed and intended for use in the provision of fertility treatment, including the storage or transport of reproductive genetic material, has a statutory right under this Act, without prohibition, limitation, interference, or impediment, to the extent that such prohibition, limitation, interference, or impediment in any way or degree obstructs, delays, or affects commerce over which the Federal Government has jurisdiction, to manufacture, import, market, sell, and distribute such drug or device.

1	(b) STATE REGULATION OF MEDICINE.—The en-
2	forcement of State health and safety law regarding med-
3	ical facilities or health care providers does not constitute
4	a violation of subsection (a) if—
5	(1) such regulations are in accordance with
6	widely accepted and evidence-based medical stand-
7	ards of care for providing fertility treatment; and
8	(2) the safety or health objective cannot be ad-
9	vanced by a different means that does not prohibit
10	limit, interfere with, or impede the rights described
11	in subsection (a).
12	(c) Enforcement.—
13	(1) The attorney general.—
14	(A) In General.—The Attorney General
15	may commence a civil action on behalf of the
16	United States against any State; an individual
17	employee, official, agency head, contractor, or
18	ganization, or instrumentality acting for, or or
19	behalf of, such a State; or any individual acting
20	under the color of, or pursuant to, State law
21	that implements, enforces, or threatens to en-
22	force a limitation or requirement that prohibits
23	limits, interferes with, or impedes the statutory

rights of an individual, a health care provider,

TAM25686 3S5

1	a health insurance issuer, or a manufacturer
2	under subsection (a).
3	(B) Effect of violations.—The court
4	shall hold unlawful and set aside a limitation or
5	requirement described in subparagraph (A) if it
6	is in violation of subsection (a).
7	(2) Private right of action.—
8	(A) IN GENERAL.—Any individual or entity
9	adversely affected by an alleged violation of
10	subsection (a) may commence a civil action
11	against an individual, employee, official, agency
12	head, contractor, organization, or instrumen-
13	tality acting for, or on behalf of, such a State
14	that enacts, implements, or enforces a limita-
15	tion or requirement that prohibits, limits, inter-
16	feres with, or impedes the statutory rights of an
17	individual, a health care provider, a health in-
18	surance issuer, or a manufacturer under sub-
19	section (a).
20	(B) Effect of violations.—The court
21	shall hold unlawful and enjoin a limitation or
22	requirement described in subparagraph (A) if it
23	is in violation of subsection (a).
24	(3) Health care provider.—

1	(A) In general.—A health care provider
2	may commence a civil action for relief on such
3	provider's own behalf, on behalf of the pro-
4	vider's staff, or on behalf of the provider's pa-
5	tients who are or may be adversely affected by
6	an alleged violation of subsection (a).
7	(B) EFFECT OF VIOLATIONS.—The court
8	shall hold unlawful and enjoin a limitation or
9	requirement described in subparagraph (A) if it
10	is in violation of subsection (a).
11	(4) Equitable relief.—In any action under
12	this section, the court may award appropriate equi-
13	table relief, including temporary, preliminary, or per-
14	manent injunctive relief.
15	(5) Costs.—
16	(A) IN GENERAL.—In any action under
17	this section, the court shall award costs of liti-
18	gation, as well as reasonable attorney's fees, to
19	any prevailing plaintiff.
20	(B) Liability of plaintiffs.—A plain-
21	tiff shall not be liable to a defendant for costs
22	or attorney's fees in any non-frivolous action
23	under this section unless such costs or attor-
24	ney's fees are imposed by the court as part of

S.L.C. TAM25686 3S5

1	sanctions for violations committed during the
2	discovery process.
3	(6) Jurisdiction.—The district courts of the
4	United States shall have jurisdiction over pro-
5	ceedings under this section and shall exercise the
6	same without regard to whether the party aggrieved
7	shall have exhausted any administrative or other
8	remedies that may be provided for by law.
9	(7) Right to remove.—
10	(A) IN GENERAL.—Any party shall have a
11	right to remove an action brought under this
12	subsection to the district court of the United
13	States for the district and division embracing
14	the place where such action is pending.
15	(B) REVIEW.—An order remanding the
16	case to the State court from which it was re-
17	moved under this paragraph is immediately re-
18	viewable by appeal or otherwise.
19	(d) Rules of Construction.—
20	(1) In general.—For purposes of this Act, a
21	State law, or the administration, implementation, or
22	enforcement of a State law, constitutes a prohibi-
23	tion, limitation, interference, or impediment on a
24	health care provider choosing to provide, an indi-
25	vidual choosing to receive, a health insurance issuer

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

TAM25686 3S5 S.L.C.

choosing to cover, or a manufacturer choosing to market drugs or devices for fertility treatment, provided in accordance with widely accepted and evidence-based medical standards of care, as described in section 4, if the administration, implementation, interpretation, or enforcement of such law has an effect that— (A) imposes requirements or limitations that are inconsistent with providing, receiving, providing health insurance coverage for, or providing drugs or devices for fertility treatment in accordance with widely accepted and evidencebased medical standards of care or that otherwise violate the purpose and requirements of this Act, which may include— (i) requiring that a health care provider provide, and patients undertake, medically unnecessary procedures and services, including tests and procedures, providing medically inaccurate information regarding fertility treatment, or requiring additional unnecessary in-person visits to a health care provider, that are inconsistent with widely accepted and evidence-based medical standards of care;

1	(ii) imposing limitations or require-
2	ments concerning physical offices, clinics,
3	facilities, equipment, staffing, or hospital
4	transfer arrangements of facilities where
5	fertility treatment is provided, or the cre-
6	dentials or hospital privileges or status of
7	personnel at such facilities, that are not
8	consistent with widely accepted and evi-
9	dence-based medical standards of care; or
10	(iii) limiting a health care provider's
11	right or ability to choose to provide, or a
12	patient's right to choose to receive, or im-
13	posing limitations that reduce the efficacy
14	of, fertility treatment in accordance with
15	widely accepted and evidence-based medical
16	standards of care, including retrieval of
17	multiple eggs during oocyte retrieval; per-
18	formance of insemination procedures, in-
19	cluding intrauterine insemination;
20	intracytoplasmic sperm injections to fer-
21	tilize multiple human eggs; and
22	cryopreservation of one or more eggs or
23	embryos for fertility preservation, if deter-
24	mined appropriate by the health care pro-
25	vider and patient;

1 (B) infringes, limits, or restricts the ability 2 of a health care provider, patient, health insur-3 ance issuer, or manufacturer, to exercise or en-4 force their statutory rights under this Act on 5 the basis of marital status, sex (including sex-6 ual orientation and gender identity) or any 7 other protected class that is covered by Federal 8 law; 9 (C) limits a health care provider's or pa-10 tient's right or ability to determine the most ap-11 propriate disposition of reproductive genetic 12 materials, including by defining reproductive 13 genetic materials in such a way as to prevent 14 or restrict options for the health care provider 15 or patient; 16 (D) limits a health care provider's ability 17 to provide, or a patient's ability to receive, fer-18 tility treatment via telemedicine, in accordance 19 with widely accepted and evidence-based med-20 ical standards of care; 21 (E) limits or prohibits a health care pro-22 vider's ability to provide, or a patient's ability 23 to receive, fertility counseling or fertility treat-24 ment based on the residency of the patient, or 25 prohibits or limits the ability of any individual

1 to assist or support a patient seeking fertility 2 treatment; 3 (F) imposes requirements or limitations 4 that compel health care providers to provide, or 5 patients to receive, medically unnecessary care, 6 or withhold medically necessary care, in a man-7 ner that is not consistent with widely accepted 8 and evidence-based medical standards of care 9 for fertility treatment, including mandating the 10 transfer of embryos that a health care provider 11 would not reasonably expect, based on widely 12 accepted and evidence-based medical standards 13 of care, to lead to a healthy pregnancy or a live 14 birth; 15 (G) limits a health care provider's right or 16 ability to prescribe or dispense, or a patient's 17 right or ability to receive or use, medications 18 for fertility treatment in accordance with widely 19 accepted and evidence-based medical standards 20 of care, unless such a limitation is generally ap-21 plicable to the prescription, dispensing, or dis-22 tribution of medications; or 23 (H) limits a health care provider's right or ability to perform a human sperm retrieval pro-24

cedure in accordance with widely accepted and evidence-based medical standards of care.

(2) CLARIFICATION.—The descriptions of specific State laws that would violate the statutory rights and protections described in paragraph (1) shall not be construed to limit potential violations of the statutory rights and protections under this Act to only the restrictions and limitations listed in paragraph (1), and potential violations of this Act may result from novel State restrictions and limitations that are not listed under paragraph (1).

(3) EXCLUSION.—It shall not constitute a prohibition, limitation, interference, or impediment to a health care provider providing, an individual receiving, a health insurance issuer covering, or a manufacturer marketing a drug or device for purposes of, fertility treatment under this Act for an entity to act in compliance with the Food and Drug Administration's regulation of drugs, devices, biological products, human cells, tissues, or cellular or tissue-based products used in fertility treatment, consistent with widely accepted and evidence-based medical standards of care for fertility treatment.

24 SEC. 5. APPLICABILITY AND PREEMPTION.

25 (a) IN GENERAL.—

1	(1) General application.—
2	(A) EFFECT ON STATE LAW.—This Act su-
3	persedes any State law that is inconsistent with
4	the statutory rights established under this Act
5	and precludes the implementation of such a
6	law, whether statutory, common law, or other-
7	wise, and whether adopted before or after the
8	date of enactment of this Act.
9	(B) Prohibition.—No State shall admin-
10	ister, implement, or enforce any law, rule, regu-
11	lation, standard, or other provision having the
12	force and effect of law that conflicts with any
13	provision of this Act, notwithstanding any other
14	provision of Federal law.
15	(2) Exclusion.—Preemption of State law
16	under paragraph (1) does not apply to—
17	(A) State law regarding the resolution of
18	disputes between 2 individuals with rights de-
19	scribed in section $4(a)(1)$ with respect to the
20	same reproductive genetic material; or
21	(B) any other State law, to the extent that
22	such law does not conflict with this Act and
23	protects an individual's right and ability to re-
24	ceive fertility treatment in accordance with
25	widely accepted and evidence-based medical

1 standards of care, including any such law that 2 holds a health care provider accountable for not 3 providing fertility treatment in accordance with 4 widely accepted and evidence-based medical 5 standards of care. 6 (3)Preservation OF FEDERAL PUBLIC 7 HEALTH AUTHORITIES.—Nothing in this Act shall 8 have the effect of superseding, negating, or limiting 9 provisions of Federal law, including the Federal 10 Food, Drug, and Cosmetic Act (21 U.S.C. 301 et 11 seq.) or the Public Health Service Act (42 U.S.C. 12 201 et seq.), and regulations promulgated under 13 such statutes, with respect to the regulation of 14 drugs, devices, biological products, human cells, tissues, or cellular or tissue-based products used in fer-15 16 tility treatment. 17 (4) Preservation of Hipaa Rules.—Nothing 18 in this Act shall have the effect of superseding, ne-19 gating, or limiting the provisions of the privacy, se-20 curity, and breach notification regulations in parts 21 160 and 164 of title 45, Code of Federal Regula-22 tions (or successor regulations). 23 (5) Subsequently enacted federal legis-24 LATION.—Federal statutory law adopted after the

date of the enactment of this Act is subject to this

1 Act unless such law explicitly excludes such applica-

- 2 tion by reference to this Act.
- 3 (b) Defense.—In any cause of action against an in-
- 4 dividual or entity who is subject to a limitation or require-
- 5 ment that violates this Act, in addition to the remedies
- 6 specified in section 4(c), this Act shall also apply to, and
- 7 may be raised as a defense by, such an individual or entity.